The role of high-resolution manometry in the assessment of upper gastrointestinal involvement in systemic sclerosis: a systematic review
Systemic sclerosis (SSc) affects the upper gastrointestinal (GI) system in 90% of patients. High-resolution manometry (HRM) assesses esophageal dysmotility, but its role in diagnosis and follow-up remains unclear. The objectives of this systematic review were to investigate the role of HRM in the assessment of SSc-associated upper GI involvement and to evaluate the correlation between HRM abnormalities and clinical characteristics and the effects of therapeutic interventions on HRM findings. Fifteen articles were included. Most (11/15) studies were of very good or good quality. Most studies assessed correlations between esophageal symptoms and esophageal dysmotility. Two studies assessed the effectiveness of buspirone and reported HRM findings. Studies assessing upper GI symptoms using validated questionnaires, such as the University of California Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 or Gastrointestinal Symptoms Severity Index score, found an association between absent contractility on HRM and upper GI symptoms, but even asymptomatic patients often have esophageal body dysmotility on HRM. Esophageal dysmotility positively correlates with the presence of interstitial lung disease on high-resolution computed tomography and reduced diffusion capacity (< 0.8 of predicted value). Trials investigating the effect of buspirone demonstrate both increased lower esophageal sphincter resting pressure and reduced upper GI symptoms. Most studies report on limited patient numbers and retrospective data. Potential bias was minimized using quality appraisal. HRM findings correlate to upper GI symptoms when assessed by validated questionnaires and can detect response to therapy in buspirone trials. Esophageal body dysmotility on HRM positively correlates with the presence of interstitial lung disease.
• Esophageal body dysmotility on HRM correlates with presence of ILD.
• HRM findings seem to correspond to clinical symptom alleviation in interventional trials, but data are still limited.
• At present HRM, a procedure with a high negative burden to the patient, offers little to no role in the therapeutic strategy.
KeywordsCREST Gastrointestinal High-resolution manometry Scleroderma Systemic sclerosis
Jean-Baptiste Vulsteke holds an FWO SB fellowship and has received support from the Fund Joël Hurlet.
Compliance with ethical standards
- 2.Volkmann ER, Tashkin DP, Sim M et al (2018) Determining progression of scleroderma-related interstitial lung disease. J Scleroderma Relat Disord. https://doi.org/10.1177/23971983188169153
- 4.Schmeiser T, Saar P, Jin D, Noethe M, Müller A, Soydan N, Hardt PD, Jaeger C, Distler O, Roeb E, Bretzel RG, Müller-Ladner U (2012) Profile of gastrointestinal involvement in patients with systemic sclerosis. Rheumatol Int 32:2471–2478. https://doi.org/10.1007/s00296-011-1988-6 CrossRefPubMedGoogle Scholar
- 5.Pandolfino JE (2010) High-resolution manometry: is it better for detecting esophageal disease? Gastroenterol Hepatol (N Y) 6:632–634Google Scholar
- 6.Carlson DA, Pandolfino JE (2015) High-resolution manometry in clinical practice. Gastroenterol Hepatol (N Y) 11:374–384Google Scholar
- 7.Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJ, Pandolfino JE, International High Resolution Manometry Working Group (2015) The Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 27:160–174. https://doi.org/10.1111/nmo.12477 CrossRefPubMedGoogle Scholar
- 12.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100. https://doi.org/10.1371/journal.pmed.1000100 CrossRefPubMedPubMedCentralGoogle Scholar
- 13.(1980) Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–90Google Scholar
- 21.Luciano L, Granel B, Bernit E et al (2016) Oesophageal and anorectal involvement in systemic sclerosis: a systematic assessment high resolution manometry. Clin Exp RheumatolGoogle Scholar
- 25.Karamanolis GP, Denaxas K, Panopoulos S et al (2017) Severe oesophageal disease and its associations with systemic sclerosis. Clin Exp RheumatolGoogle Scholar
- 29.Vettori S, Tolone S, Capocotta D, Chieffo R, Giacco V, Valentini G, Docimo L (2018) Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value. Clin Rheumatol 37:1239–1247. https://doi.org/10.1007/s10067-018-4026-1 CrossRefPubMedGoogle Scholar
- 31.Karamanolis GP, Panopoulos S, Denaxas K, Karlaftis A, Zorbala A, Kamberoglou D, Ladas SD, Sfikakis PP (2016) The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial. Arthritis Res Ther 18:1–6. https://doi.org/10.1186/s13075-016-1094-y CrossRefGoogle Scholar
- 37.Sallam H, McNearney TA, Chen JDZ (2006) Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol TherGoogle Scholar